Comment on Matasar et al , page 499 Ofatumumab in diffuse large B cell lymphoma ?

In this issue of Blood, Matasar and colleagues report the results of salvage treatments with anti-CD20 ofatumumab in combination with ifosfamide, carboplatinum, etoposide (ICE) or dexamethasone, high-dose cytarabine, cisplatin (DHAP) in relapsed refractory diffuse large B-cell lymphoma (DLBCL) before transplantation. They conclude that replacing rituximab with ofatumumab in second-line therapy is a promising approach.

[1]  I. Lossos,et al.  Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. , 2013, Blood.

[2]  N. Schmitz,et al.  Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Bingshu E. Chen,et al.  Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12 , 2012 .

[4]  G. Salles,et al.  Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. , 2012, Blood.

[5]  A. Hagenbeek,et al.  Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. , 2012, Blood.

[6]  C. Gisselbrecht,et al.  Relapses, treatments and new drugs. , 2012, Best practice & research. Clinical haematology.

[7]  T. Molina,et al.  Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.

[8]  C. Gisselbrecht,et al.  Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. , 2010, Clinical lymphoma, myeloma & leukemia.

[9]  A. Zelenetz,et al.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.